Cargando…

Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

Background: Atopic dermatitis is a chronic, relapsing and remitting disease that can be difficult to treat despite a recently approved biologic therapy targeting IL-4/IL-13 receptor. Oral janus kinase inhibitors (JAKi) represent a novel therapeutic class of targeted therapy to treat moderate-to-seve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le, Michelle, Berman-Rosa, Melissa, Ghazawi, Feras M., Bourcier, Marc, Fiorillo, Loretta, Gooderham, Melinda, Guenther, Lyn, Hanna, Sameh, Hong, H. Chih-Ho, Landells, Ian, Lansang, Perla, Marcoux, Danielle, Wiseman, Marni C., Yeung, Jensen, Lynde, Charles, Litvinov, Ivan V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440866/ https://www.ncbi.nlm.nih.gov/pubmed/34540860 http://dx.doi.org/10.3389/fmed.2021.682547

Ejemplares similares

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
por: Ghazawi, Feras M., et al.
Publicado: (2021)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review
por: Papp, Kim A., et al.
Publicado: (2021)

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report
por: Lansang, Rafael Paolo, et al.
Publicado: (2023)

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
por: Lytvyn, Yuliya, et al.
Publicado: (2023)

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial
por: Gooderham, Melinda J., et al.
Publicado: (2019)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis
por: Eshtiaghi, Panteha, et al.
Publicado: (2018)

Treatment of Atopic Dermatitis, Dermatophytes, and Syphilis by Indigenous Peoples Prior to 1850
por: Perlmutter, Jonah, et al.
Publicado: (2021)

35181 Baseline disease and population characteristics associated with a diagnosis of COVID 19: Data from the PURE registry
por: Albrecht, Lorne, et al.
Publicado: (2022)

Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
por: Singh, Rhea, et al.
Publicado: (2020)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Editorial: The Emerging Role of Artificial Intelligence in Dermatology
por: Mahmood, Farhan, et al.
Publicado: (2021)

A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis
por: Lee, Sang-Doo, et al.
Publicado: (2022)

Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis
por: Alves, Carlos, et al.
Publicado: (2023)

Sleep Disturbances in Children With Atopic Dermatitis: A Scoping Review
por: Lee, Dong Goo, et al.
Publicado: (2023)

Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta‐analysis
por: Lee, Kevin P., et al.
Publicado: (2022)

Acne keloidalis nuchae in a patient with atopic dermatitis treated with Janus kinase inhibitor upadacitinib
por: Caudrelier, Nicolas, et al.
Publicado: (2023)

National trends in incidence and geographic distribution of melanoma and keratinocyte carcinoma in the Russian Federation
por: Muntyanu, Anastasiya, et al.
Publicado: (2023)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
por: WOLLENBERG, Andreas, et al.
Publicado: (2022)

Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials
por: Tsai, Hou-Ren, et al.
Publicado: (2021)

Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib
por: Nguyen, Jannett, et al.
Publicado: (2020)

Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
por: Li, Chenyang, et al.
Publicado: (2022)

Investigation of the Incidence and Geographic Distribution of Bone and Soft Tissue Sarcomas in Canada: A National Population-Based Study
por: Alkazemi, Badria, et al.
Publicado: (2023)

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
por: Gooderham, Melinda J., et al.
Publicado: (2023)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
por: Gooderham, Melinda J., et al.
Publicado: (2022)

Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis
por: Chen, Qianyu, et al.
Publicado: (2023)

Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL)
por: Ghazawi, Feras M., et al.
Publicado: (2019)

Investigation of incidence and geographic distribution of gliomas in Canada from 1992 to 2010: a national population-based study highlighting the importance of exposure to airport operations
por: Ji, Xinyu, et al.
Publicado: (2023)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Eruptive halo nevi and new-onset vitiligo post-COVID-19 infection
por: Pastukhova, Elena, et al.
Publicado: (2023)

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
por: Papp, Kim A., et al.
Publicado: (2016)

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
por: Stein Gold, Linda, et al.
Publicado: (2023)

Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis
por: SEDEH, Farnam B., et al.
Publicado: (2022)

Use of risankizumab in two HIV-positive patients with psoriasis
por: Maliyar, Khalad, et al.
Publicado: (2023)

A study of meiomitosis and novel pathways of genomic instability in cutaneous T-cell lymphomas (CTCL)
por: Tsang, Matthew, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q63fnf7s3k8sejfu3blj9l843b